Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part III
Emmanuel J. Favaloro, Giuseppe Lippi
Abstract
Welcome to another issue of Seminars in Thrombosis and Hemostasis (STH). This issue is published under the "continuing banner" of "Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)," this being Part III, or the third such issue. The first two issues were respectively published in 2020 1 and 2021 2 and proved very popular with the STH readership. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Believed to originate from Wuhan City in China, with the first reported case in December 2019, at time of writing, there were over 200 million cases reported worldwide, and over 4.3 million attributable deaths. 3 This compares with 113 million cases reported worldwide, and over 2.5 million attributable deaths, at the time of writing the second issue's Preface (February 27 th , 2021), 2 and 26 million cases reported worldwide, and nearly 900,000 attributable deaths, at the time of writing the first COVID-19 issue Preface (August 30th, 2020). 1 From a smattering of reports in the scientific literature in late 2019 (n 228), there are now over 165,000 publications ascribed to COVID-19 in PubMed, including over 18,000 reviews. This compares to 100,000 publications, including almost 12,000 reviews, at time of writing the second COVID-19 issue Preface, 2 and 51,000 publications, including over 5000 reviews, at time of writing the first COVID-19 issue Preface. 1 Thus, cases of COVID-19 have grown fourfold, and attributable deaths over threefold, since writing the first Preface. 5]